Share on StockTwits

Halozyme Therapeutics (NASDAQ:HALO) Director John Stuart Patton sold 75,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $9.96, for a total value of $747,000.00. Following the completion of the sale, the director now directly owns 179,876 shares in the company, valued at approximately $1,791,565. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Halozyme Therapeutics in a research note on Friday, July 11th. They set an “overweight” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $11.13.

Shares of Halozyme Therapeutics (NASDAQ:HALO) traded down 3.28% on Thursday, hitting $9.43. The stock had a trading volume of 1,011,266 shares. Halozyme Therapeutics has a one year low of $6.88 and a one year high of $18.18. The stock has a 50-day moving average of $9.52 and a 200-day moving average of $10.39. The company’s market cap is $1.167 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.01. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $13.71 million. During the same quarter last year, the company posted ($0.20) earnings per share. Halozyme Therapeutics’s revenue was up 27.2% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics will post $-0.61 EPS for the current fiscal year.

Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.